Earnings summaries and quarterly performance for Acrivon Therapeutics.
Executive leadership at Acrivon Therapeutics.
Peter Blume-Jensen
Detailed
Chief Executive Officer and President
CEO
AL
Adam Levy
Detailed
Chief Financial Officer
ED
Eric Devroe
Detailed
Chief Operating Officer
EG
Erick Gamelin
Detailed
Chief Development Officer
KM
Kristina Masson
Detailed
Executive Vice President, Business Operations
MR
Mansoor Raza Mirza
Detailed
Chief Medical Officer
MM
Mary-Alice Miller
Detailed
Chief Legal Officer
Board of directors at Acrivon Therapeutics.
Research analysts covering Acrivon Therapeutics.
Recent press releases and 8-K filings for ACRV.
Acrivon Therapeutics Reports Positive Phase 2b Data for ACR-368 and Advances Clinical Programs
ACRV
New Projects/Investments
- Acrivon Therapeutics announced positive data from its ACR-368 Phase 2b registrational-intent trial, showing a 39% overall response rate in endometrial cancer and a 52% confirmed response rate in serous subtype patients with up to two prior lines of therapy.
- The company has submitted an EU Clinical Trial Application for Arm 3 enrollment for ACR-368 across more than 20 European sites, with enrollment completion anticipated in Q4 2026.
- Acrivon Therapeutics also submitted a Phase 3 confirmatory protocol to the FDA for ACR-368 combined with anti-PD-1 therapy in frontline endometrial cancer.
- Initial ACR-2316 Phase 1 data showed tumor shrinkage in endometrial cancer, SCLC, and squamous NSCLC, and ACR-6840 was nominated as its next CDK11 inhibitor development candidate.
Jan 28, 2026, 2:15 PM
Acrivon Therapeutics, Inc. Provides Clinical Data and Pipeline Updates
ACRV
New Projects/Investments
Guidance Update
- Acrivon Therapeutics, Inc. reported positive clinical data for ACR-368 in endometrial cancer, with an Overall Response Rate (ORR) of 39% for single-agent therapy in OncoSignature-positive subjects, and anticipates completing enrollment for the biomarker-unselected serous cohort in Q4 2026. A Phase 3 trial design for ACR-368 plus anti-PD-1 in frontline treatment has been submitted to the FDA.
- Initial Phase 1 clinical data for ACR-2316 demonstrated favorable tolerability and clinical activity in AP3-predicted solid tumor types, including small cell lung cancer (SCLC) and squamous non-small cell lung cancer (sqNSCLC), which have not previously shown sensitivity to other WEE1 or PKMYT1 inhibitors.
- The company nominated ACR-6840 as a new cell cycle program development candidate, a potential first-in-class CDK11 inhibitor, with an Investigational New Drug (IND) submission planned for Q4 2026.
- As of December 31, 2025, Acrivon Therapeutics, Inc. had approximately $119 million in cash and investments, providing a projected runway into Q2 2027.
Jan 8, 2026, 2:00 PM
Acrivon Therapeutics Provides Clinical Data Updates for ACR-368 and ACR-2316, and AP3 Pipeline Updates
ACRV
New Projects/Investments
Product Launch
- In the ongoing Phase 2b trial for endometrial cancer, ACR-368 monotherapy demonstrated an Overall Response Rate (ORR) of 39% in OncoSignature-positive (BM+) subjects, with an ORR of 67% for the serous subtype within this group.
- Enrollment for Arm 3 of the ACR-368 trial (all-comer serous EC, US+EU) is anticipated to be completed in Q4 2026.
- ACR-2316 showed initial clinical activity in its Phase 1 monotherapy dose-escalation study, with tumor shrinkage observed in 9 out of 20 evaluable patients, including those with SCLC and squamous NSCLC, at doses of 120 mg and above.
- Acrivon disclosed ACR-6840 as a new preclinical development candidate, which is a potential first-in-class, potent, selective CDK11 oral inhibitor.
Jan 8, 2026, 1:30 PM
Acrivon Therapeutics Announces Positive Clinical Data for ACR368 and ACR2316, Introduces New Candidate ACR6840, and Updates Financials
ACRV
New Projects/Investments
Guidance Update
- Acrivon Therapeutics reported an overall response rate of 52% in the serous all-comer population with up to two prior lines of therapies in its ongoing phase 2b trial for ACR368 in endometrial cancer, and a phase 3 confirmatory trial protocol was submitted to the FDA on November 12, 2025.
- The company's internally developed ACR2316 showed initial clinical activity in AP3-selected solid tumors, including small cell lung cancer and squamous non-small cell lung cancer, with a favorable tolerability profile in its phase 1 monotherapy dose escalation study.
- Acrivon introduced ACR6840, a new preclinical cell cycle development candidate targeting CDK11, with an Investigational New Drug (IND) submission guided for Q4 2026.
- As of December 31, 2025, Acrivon Therapeutics had approximate cash and investments of $119 million, with a projected financial runway into Q2 2027.
Jan 8, 2026, 1:30 PM
Acrivon Therapeutics Announces Clinical Data Updates, New Development Candidate, and Financial Outlook
ACRV
New Projects/Investments
Guidance Update
- Acrivon Therapeutics reported an overall response rate of 52% in the serous all-comer population with up to two prior lines of therapy in its ongoing Phase 2b trial for ACR368 in endometrial cancer, leading to the initiation of an arm three for biomarker-unselected serous endometrial cancer subjects. A Phase 3 confirmatory trial protocol for ACR368 was submitted to the FDA on November 12, 2025.
- Initial Phase 1 clinical data for ACR2316, an internally developed dual WEE1/PKMYT1 inhibitor, showed tumor shrinkage in 9 out of 20 patients and partial remissions in aggressive cancers like small cell lung cancer and squamous non-small cell lung cancer.
- The company disclosed a new preclinical cell cycle development candidate, ACR6840, which targets CDK11, with an Investigational New Drug (IND) submission guided for Q4 2026.
- As of December 31, 2025, Acrivon reported approximate cash and investments of $119 million, with a projected financial runway extending into Q2 2027.
Jan 8, 2026, 1:30 PM
Acrivon Therapeutics announces positive clinical data for lead programs and new preclinical candidate
ACRV
New Projects/Investments
Guidance Update
- Acrivon Therapeutics reported a 52% confirmed overall response rate in the serous all-comer population with up to two prior lines of therapies in its Phase II-B trial for ACR-368 in endometrial cancer. An arm three has been initiated for biomarker-unselected serous endometrial cancer, which is considered a potentially faster path to approval.
- The company submitted a Phase III confirmatory trial protocol to the FDA on November 12, 2025, for ACR-368 in combination with anti-PD-1 in the maintenance phase for pMMR endometrial cancer.
- For ACR-2316, initial clinical activity was observed in AP3-selected solid tumor types, including small cell lung cancer and squamous non-small cell lung cancer, with a favorable tolerability profile.
- Acrivon introduced ACR-6840, a new preclinical development candidate targeting CDK11, with an IND submission guided for Q4 2026.
- As of December 31, 2025, Acrivon had approximate cash and investments of $119 million, with a projected runway into Q2 2027.
Jan 8, 2026, 1:30 PM
Acrivon Therapeutics Announces Positive Clinical Data and Financial Update
ACRV
New Projects/Investments
Guidance Update
- Acrivon Therapeutics reported preliminary unaudited cash, cash equivalents, and investments of approximately $119 million as of December 31, 2025, which is expected to fund operations into the second quarter of 2027.
- The company announced positive ACR-368 Phase 2b endometrial cancer clinical data, showing a 39% overall response rate (ORR) in monotherapy BM+ subjects and a 52% confirmed ORR (cORR) in all-comer subjects with serous subtype and up to two prior lines of therapy. A Phase 3 confirmatory protocol for ACR-368 plus anti-PD-1 therapy in frontline EC subjects has been submitted to the FDA, with global trial readiness expected mid-2026.
- Initial Phase 1 clinical data for ACR-2316, a WEE1/PKMYT1 inhibitor, demonstrated favorable tolerability and tumor shrinkage in 9 out of 20 evaluable patients, including partial responses in endometrial cancer, SCLC, and sqNSCLC.
- ACR-6840, a potential first-in-class CDK11 inhibitor, was nominated as the next AP3-enabled development candidate, with IND submission anticipated in the fourth quarter of 2026.
Jan 8, 2026, 12:30 PM
Acrivon Therapeutics Reports Q3 2025 Financial Results and Business Highlights
ACRV
Earnings
New Projects/Investments
Guidance Update
- Acrivon Therapeutics, Inc. reported a net loss of $18.2 million for the third quarter ended September 30, 2025, an improvement from a net loss of $22.4 million for the same period in 2024.
- Research and development expenses decreased to $13.6 million for Q3 2025, compared to $18.9 million in Q3 2024, mainly due to fewer scheduled milestones and a focus on endometrial cancer in the ACR-368 clinical trial.
- As of September 30, 2025, the company had $134.4 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations into the second quarter of 2027.
- The company is continuing to advance its ACR-368 program in a registrational-intent Phase 2b trial for endometrial cancer and is preparing to disclose initial clinical data for ACR-2316 from its Phase 1 trial later in 2025.
Nov 13, 2025, 9:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more